Plain-English translation of NCT06868290 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a new treatment called (YTB323) for people with severe, active granulomatosis with polyangiitis (GPA) or microscopic polyangiitis (MPA)—both conditions where the immune system mistakenly attacks blood vessels. The medication is a type of cell therapy that works by modifying your own immune cells to fight the disease. Researchers want to see whether this treatment works better than current standard treatments, and whether it is safe.
GPA and MPA are serious autoimmune diseases that can damage vital organs if not controlled. Current treatments work for some people, but not everyone responds well, and some people cannot tolerate them. This trial exists to find out whether this new cell-based treatment can offer people with severe disease a better option with fewer side effects.
If you join, you'll be randomly assigned to receive either the new cell therapy or a standard comparator treatment, both given with glucocorticoid medications as part of the study protocol. You will receive a single infusion of your assigned treatment and then be monitored during the study. If you receive the new cell therapy, you'll also be asked to participate in long-term follow-up visits for up to 15 years after your infusion to make sure the treatment remains safe and effective over time.
AI-generated summary from trial data · Sep 5, 2026 · Not medical advice
United States